keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy-induced thrombocytopenia

keyword
https://www.readbyqxmd.com/read/29776985/tkaczynski-e-arulselvan-a-tkaczynski-j-et-al-2-o-3-o-desulfated-heparin-mitigates-murine-chemotherapy-and-radiation-induced-thrombocytopenia-blood-adv-2018-2-7-754-761
#1
https://www.readbyqxmd.com/read/29754293/chemotherapy-induced-neutropenia-as-a-prognostic-and-predictive-marker-of-outcomes-in-solid-tumor-patients
#2
REVIEW
Pashtoon Murtaza Kasi, Axel Grothey
Chemotherapy-induced neutropenia (CIN) is one of the most common side effects seen in cancer patients. As an adverse event, it is deemed undesirable since it often constitutes a dose-limiting toxicity for cytotoxic agents leading to treatment delays and/or dose reductions. It is also associated with a financial cost component from diagnostic work-up and treatment of patients with chemotherapy-induced febrile neutropenia (CIFN). Neutropenia is commonly accompanied by a decrease in other hematopoietic lineages (anemia and/or thrombocytopenia)...
May 12, 2018: Drugs
https://www.readbyqxmd.com/read/29666579/d-dencichine-regulates-thrombopoiesis-by-promoting-megakaryocyte-adhesion-migration-and-proplatelet-formation
#3
Shilan Ding, Min Wang, Song Fang, Huibo Xu, Huiting Fan, Yu Tian, Yadong Zhai, Shan Lu, Xin Qi, Fei Wei, Guibo Sun, Xiaobo Sun
Life-threatening chemotherapy-induced thrombocytopenia can increase the risk of bleeding due to a dramatic low platelet count, which may limit or delay treatment schedules in cancer patients. The pressing need for the rapid alleviation of the symptoms of thrombocytopenia has prompted us to search for novel highly effective and safe thrombopoietic agents. Pharmacological investigations have indicated that dencichine can prevent and treat blood loss and increase the number of platelets. On the basis of the neurotoxicity of dencichine, D-dencichine is artificially synthesized in the laboratory...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29664688/predictive-value-of-cd4-cd8-ratio-in-patients-with-breast-cancer-receiving-recombinant-human-thrombopoietin
#4
Junnan Xu, Lei Jiang, Hui Cao, Yufeng Jia, Shuo Wu, Cui Jiang, Tao Sun
Recombinant human thrombopoietin (rhTPO) is a key determinant of therapy for chemotherapy-induced thrombocytopenia (CIT) in patients with breast cancer. To assess the predictive value of preoperative inflammatory cells for response to rhTPO in breast cancer patients, a total of 198 female patients with breast cancer were enrolled between June 2011 and December 2016 in Liaoning Cancer Hospital. Peripheral blood samples before rhTPO therapy were obtained, the ratios of helper T cell (CD4+ ), cytotoxic T cell (CD8+ ), NK cell (CD16+ /CD56+ ), and B cell (CD19+ ) were analyzed, and CD4/CD8 ratios were calculated...
April 17, 2018: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/29656748/nivolumab-induced-severe-pancytopenia-in-a-patient-with-lung-adenocarcinoma
#5
Kentaro Tokumo, Takeshi Masuda, Takahiko Miyama, Shinichiro Miura, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Taku Nakashima, Shintaro Miyamoto, Takashi Yoshida, Hiroshi Iwamoto, Kazunori Fujitaka, Hironobu Hamada, Noboru Hattori
Severe leukopenia, thrombocytopenia, and bi-cytopenia due to nivolumab have been reported. In this report, we present the first case of nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. A 56-year-old Japanese man with lung adenocarcinoma received nivolumab therapy as second-line treatment. After 3 cycles of this therapy, although computed tomography (CT) showed a reduced tumor size, laboratory findings revealed pancytopenia and a bone marrow biopsy showed a severely hypoplastic marrow...
May 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29599195/2-o-3-o-desulfated-heparin-mitigates-murine-chemotherapy-and-radiation-induced-thrombocytopenia
#6
Elizabeth Tkaczynski, Abinaya Arulselvan, John Tkaczynski, Stephen Avery, Liqing Xiao, Beverly Torok-Storb, Kraig Abrams, Narayanam V Rao, Gregory Johnson, Thomas P Kennedy, Mortimer Poncz, Michele P Lambert
Thrombocytopenia is a significant complication of chemotherapy and radiation therapy. Platelet factor 4 (PF4; CXCL4) is a negative paracrine of megakaryopoiesis. We have shown that PF4 levels are inversely related to steady-state platelet counts, and to the duration and severity of chemotherapy- and radiation-induced thrombocytopenia (CIT and RIT, respectively). Murine studies suggest that blocking the effect of PF4 improves megakaryopoiesis, raising nadir platelet counts and shortening the time to platelet count recovery...
April 10, 2018: Blood Advances
https://www.readbyqxmd.com/read/29501366/concurrent-chemoradiotherapy-with-nedaplatin-versus-cisplatin-in-stage-ii-ivb-nasopharyngeal-carcinoma-an-open-label-non-inferiority-randomised-phase-3-trial
#7
Lin-Quan Tang, Dong-Ping Chen, Ling Guo, Hao-Yuan Mo, Ying Huang, Shan-Shan Guo, Bin Qi, Qing-Nan Tang, Pan Wang, Xiao-Yun Li, Ji-Bin Li, Qing Liu, Yuan-Hong Gao, Fang-Yun Xie, Li-Ting Liu, Yang Li, Sai-Lan Liu, Hao-Jun Xie, Yu-Jing Liang, Xue-Song Sun, Jin-Jie Yan, Yi-Shan Wu, Dong-Hua Luo, Pei-Yu Huang, Yan-Qun Xiang, Rui Sun, Ming-Yuan Chen, Xing Lv, Lin Wang, Wei-Xiong Xia, Chong Zhao, Ka-Jia Cao, Chao-Nan Qian, Xiang Guo, Ming-Huang Hong, Zhi-Qiang Nie, Qiu-Yan Chen, Hai-Qiang Mai
BACKGROUND: Cisplatin-based concurrent chemoradiotherapy is currently considered to be the standard treatment regimen for patients with advanced nasopharyngeal carcinoma, but has well known side-effects such as gastrointestinal reactions, nephrotoxicity, and ototoxicity. Nedaplatin was developed to decrease the toxic effects induced by cisplatin, and in this trial we assessed whether a nedaplatin-based concurrent chemoradiotherapy regimen was non-inferior to a cisplatin-based regimen in patients with locoregional, stage II-IVB nasopharyngeal carcinoma...
April 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29426719/safety-and-preliminary-efficacy-of-vorinostat-with-r-epoch-in-high-risk-hiv-associated-non-hodgkin-s-lymphoma-amc-075
#8
Juan C Ramos, Joseph A Sparano, Michelle A Rudek, Page C Moore, Ethel Cesarman, Erin G Reid, David Henry, Lee Ratner, David Aboulafia, Jeanette Y Lee, Richard F Ambinder, Ronald Mitsuyasu, Ariela Noy
INTRODUCTION: Vorinostat (VOR), a histone deacetylase inhibitor, enhances the anti-tumor effects of rituximab (R) and cytotoxic chemotherapy, induces viral lytic expression and cell killing in Epstein-Barr virus-positive (EBV+ ) or human herpesvirus-8-positive (HHV-8+ ) tumors, and reactivates latent human immunodeficiency virus (HIV) for possible eradication by combination antiretroviral therapy (cART). PATIENTS AND METHODS: We performed a phase I trial of VOR given with R-based infusional EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) (n = 12) and cART in aggressive HIV-associated B-cell non-Hodgkin lymphoma (NHL) in order to identify safe dosing and schedule...
March 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29397850/-efficacy-of-recombinant-human-thrombopoietin-and-recombinant-human-interleukin-11-for-treatment-of-chemotherapy-indu-ced-thrombocytopenia-in-acute-myeloid-leukaemia-patients
#9
Guang Tang, Xiao-Min Wang, Jun-Xia Meng, Chun-Lai Luan, Jie-Fu Chen, Yong-Qiang Wu, Xiao-Nan Zhang, Zi-Yan He
OBJECTIVE: To evaluate and compare the clinical efficacy and safety of recombinant human thrombopoietin(rhTPO) and recombinant human interleukin11(rhIL-11) for the treatment of chemotherapy-induced thrombocytopenia in adult acute myeloid leukaemia patients. METHODS: Total of 96 adult acute myeloid leukaemia patients were divided into 3 groups according to randomized controlled method: rhTPO group, rhIL-11 group and control group, 32 cases in each group. The patients in rhTPO group and rhIL-11 received rhTPO of 15000 IU/d and rhIL-11 of 1...
February 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29344020/a-case-of-immune-thrombocytopenia-as-a-rare-side-effect-of-an-immunotherapy-with-pd1-blocking-agents-for-metastatic-melanoma
#10
Claudia Pföhler, Hermann Eichler, Barbara Burgard, Nathalie Krecké, Cornelia S L Müller, Thomas Vogt
Background: Checkpoint blocking agents such as pembrolizumab or nivolumab may induce a diversity of mostly autoimmune-mediated side effects. These autoimmune phenomena mainly affect ductless glands such as the pituitary gland (hypophysitis), the thyroid gland (thyreoiditis), the skin (vitiligo and rash), the colon (colitis), and the lung (pneumonitis). Furthermore, many other organs or organ systems may be affected. Case Report: This work describes a case of an immune thrombocytopenia that developed or rather became clinically significant shortly after initiation of a systemic therapy with first nivolumab and later pembrolizumab given due to metastatic melanoma...
November 2017: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/29318565/a-case-of-severe-stenosis-of-hepatic-veins-and-inferior-vena-cava-with-stomal-variceal-bleeding-induced-by-oxaliplatin-based-chemotherapy
#11
Hayato Yamaguchi, Yoshihiro Furuichi, Yoshitaka Kasai, Hirohito Takeuchi, Yuu Yoshimasu, Katsutoshi Sugimoto, Ikuo Nakamura, Takao Itoi
A 27-year-old woman with colon cancer and liver metastasis was referred to our hospital. Colectomy and colostomy were performed to improve her ileus. Following 13 sessions of oxaliplatin-based chemotherapy (OC) with mFOLFOX6 + bevacizumab, thrombocytopenia and frequent peristomal bleeding occurred. Computed tomography showed severe ascites, splenomegaly, significant collateral veins around the stoma, and severe stenosis of the hepatic veins (HV) and inferior vena cava (IVC). Ultrasound elastography showed high liver (and spleen) stiffness values...
April 2018: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/29281948/a-patient-with-oxaliplatin-immune-induced-syndrome-oiis-who-also-developed-leucovorin-and-palonosetron-associated-thrombocytopenia
#12
S A Curtis, B R Curtis, A I Lee, J E Hendrickson, J Lacy, N A Podoltsev
OBJECTIVES: We report a case of an 83 year old man who developed oxaliplatin immune-induced syndrome (OIIS) after his 19th cycle of FOLFOX (5FU, leucovorin, oxaliplatin). When oxaliplatin was omitted from his next cycle of chemotherapy he continues to show signs of drug-induced immune thrombocytopenia (DITP) and was found to have drug-dependent, platelet-reactive antibodies (DDPA) to leucovorin and palonosetron as well as oxaliplatin. METHODS: The patient was admitted for monitoring but required no transfusions and thrombocytopenia resolved without treatment during his first admission...
December 28, 2017: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/29242295/the-use-of-romiplostim-in-treating-chemotherapy-induced-thrombocytopenia-in-patients-with-solid-tumors
#13
Hanny Al-Samkari, Ariela L Marshall, Katayoon Goodarzi, David J Kuter
No abstract text is available yet for this article.
December 14, 2017: Haematologica
https://www.readbyqxmd.com/read/29220692/plag-alleviates-chemotherapy-induced-thrombocytopenia-via-promotion-of-megakaryocyte-erythrocyte-progenitor-differentiation-in-mice
#14
Ha-Reum Lee, Nina Yoo, Jinseon Jeong, Ki-Young Sohn, Sun Young Yoon, Jae Wha Kim
Previously, PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol, acetylated diglyceride) was reported to have an effect on the proliferation of hematopoietic stem cells (HSCs) or to contribute to the prevention of chemotherapy-induced neutropenia. In this study, we examined the role of PLAG in the differentiation of bone marrow cells from HSCs into progenitor cells in mice. After 15days, the lineage-negative cells, especially megakaryocyte/erythrocyte progenitors (MEP), were significantly increased in mice that received daily PLAG administration compared to those in the untreated mice...
January 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29194191/brca-mutation-status-is-not-associated-with-increased-hematologic-toxicity-among-patients-undergoing-platinum-based-chemotherapy-for-ovarian-cancer
#15
Joanne Kotsopoulos, Karla Willows, Sandra Trat, Raymond H Kim, Alexandra Volenik, Ping Sun, Steven A Narod, Jeffrey Boyd, Taymaa May
OBJECTIVE: Women with an inherited BRCA1 or BRCA2 mutation may have an impaired ability to repair chemotherapy-induced damage as a result of a state of haploinsufficiency and may experience greater treatment-related toxicity. The objective of this study was to compare the hematologic adverse effect profiles associated with platinum-based chemotherapy in ovarian cancer patients with and without germline BRCA mutations. METHODS: We conducted a retrospective analysis of patients treated for high-grade serous ovarian cancer at Princess Margaret Cancer Center, Toronto, Ontario between January 2000 and December 2015...
January 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29178132/thrombopoietin-receptor-agonists-for-prevention-and-treatment-of-chemotherapy-induced-thrombocytopenia-in-patients-with-solid-tumours
#16
REVIEW
Xia Zhang, Yunhai Chuai, Wei Nie, Aiming Wang, Guanghai Dai
BACKGROUND: Chemotherapy-induced thrombocytopenia (CIT) is defined as a peripheral platelet count less than 100×109 /L, with or without bleeding in cancer patients receiving myelosuppressive chemotherapy. CIT is a significant medical problem during chemotherapy, and it carries the risk of sub-optimal overall survival and bleeding. Alternative interventions to platelet transfusion are limited. Different stages of preclinical and clinical studies have examined the thrombopoietin receptor agonists (TPO-RAs) for CIT in patients with solid tumours...
November 27, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29172983/a-comparison-of-brand-and-biosimilar-granulocyte-colony-stimulating-factors-for-prophylaxis-of-chemotherapy-induced-febrile-neutropenia
#17
COMPARATIVE STUDY
Andrea G Douglas, Phil Schwab, Daniel Lane, Kenneth Kennedy, S Lane Slabaugh, Andy Bowe
BACKGROUND: Filgrastim-sndz, a granulocyte-colony stimulating factor (G-CSF), was introduced as a biosimilar to filgrastim in 2015, but real-world comparative effectiveness for filgrastim versus filgrastim-sndz has not been reported to date. OBJECTIVES: To (a) compare the incidence of febrile neutropenia for patients taking filgrastim versus those taking filgrastim-sndz and (b) compare the incidence of a potential serious adverse event for filgrastim versus filgrastim-sndz...
December 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29138381/-a-case-of-lung-cancer-associated-with-drug-induced-immune-thrombocytopenia
#18
Mayuka Yamane, Toshihito Otani, Yojiro Onari
A Stage IV lung adenocarcinoma was diagnosed in the left upper lobe of an 81-year-old man 2.5 years ago. Following another form of chemotherapy, he then received docetaxel as fourth-line therapy. After 21 days of therapy, although his white blood cell count recovered, his platelet count decreased to 20,000/mL and continued to decrease. Subsequently, he was closely monitored without therapy, and eventually, his platelet count returned within the normal range after 112 days. Blood biochemistry and bone marrow paracentesis findings suggested the presence of paraneoplastic syndrome, idiopathic thrombocytopenic purpura, and drug-induced immune thrombocytopenia...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29049237/effect-and-safety-of-cytokine-induced-killer-cik-cell-immunotherapy-in-patients-with-breast-cancer-a-meta-analysis
#19
Jianxin Hu, Junfeng Hu, Xiandong Liu, Chao Hu, Ming Li, Wei Han
BACKGROUND: Breast cancer (BC) is considered a systemic disease with a primarily locoregional component. The accumulation of basic researches and clinical studies related to cytokine-induced killer (CIK) cells has confirmed their safety and feasibility in treating BC. By searching the PubMed, Embase, CNKI, and Wanfang databases, we conducted a meta-analysis to assess the efficacy and safety of DC/CIK plus chemotherapy regimen (Exp) compared with chemotherapy (Con) alone regimen for breast carcinoma...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29034009/a-multicenter-randomized-study-of-decitabine-as-epigenetic-priming-with-induction-chemotherapy-in-children-with-aml
#20
Lia Gore, Timothy J Triche, Jason E Farrar, Daniel Wai, Christophe Legendre, Gerald C Gooden, Winnie S Liang, John Carpten, David Lee, Frank Alvaro, Margaret E Macy, Carola Arndt, Philip Barnette, Todd Cooper, Laura Martin, Aru Narendran, Jessica Pollard, Soheil Meshinchi, Jessica Boklan, Robert J Arceci, Bodour Salhia
BACKGROUND: Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltransferases, which has been studied extensively and is approved for myelodysplastic syndrome in adults but with less focus in children. Accordingly, we conducted a phase 1 multicenter, randomized, open-label study to evaluate decitabine pre-treatment before standard induction therapy in children with newly diagnosed AML to assess safety and tolerability and explore a number of biologic endpoints. RESULTS: Twenty-four patients were fully assessable for all study objectives per protocol (10 in Arm A = epigenetic priming induction, 14 in Arm B = standard induction)...
2017: Clinical Epigenetics
keyword
keyword
115055
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"